Our request for proposals has expired - please check later in 2016 or early in 2017 for the next opportunity. For informational purposes, you can find the 2016 RFA here. As in 2015, we used a two-step system.

Pertinent info:
- Deadline Pre-Proposals: Friday March 18, 12 Noon (we will distribute proposals Friday afternoon to the reviewers, before the weekend)
- Full proposals will be sollicited from selected PIs by late March
- Deadline full proposals will be May 9; start date July 1
- Awards are for 2 years, $50,000 per year
- All UAB faculty and SR scientists are eligible to apply
- Only small molecule-directed efforts are considered responsive to this RFA

The ADDA offers pilot funding opportunities in collaboration with the UAB Center for Emerging Drug Discovery, the UAB Center for Clinical and Translational Science and with the UAB Comprehensive Cancer Center. Grants are for $50,000 per year for 2 years, with the second year of funding dependent on progress made in the first year. Funds can be utilized for any aspect of drug discovery and development, including - but not limited to - target validation, assay development for high-throughput screening, molecular modeling and medicinal chemistry efforts, or proof of concept studies in animals. Upon funding, a multi-disciplinary team will be assembled, consisting of members with relevant expertise, including cell biology, pharmacology, medicinal chemistry, HTS assay development as well as clinical knowledge. This team, which will meet quarterly, will help create a compound progression pathway and guide the project through the drug discovery and development pipeline. In addition to scientific merit, applications will be evaluated for intellectual property and commercialization aspects, in collaboration with the Bill L. Harbert Institute for Innovation and Entrepreneurship (IIE) and Southern Research.

RFA Full Proposals.pdf